Table 1.
Effect of DOXO (10 mg/kg; i.p.) or DZX (20 mg/kg; i.p.) or combined DZX+DOXO treatment on Ejection Fraction (% EF), Fraction Shortening (% FS), Left Ventricular End-Diastolic Diameter (LVEDD) and on Left Ventricular End-Systolic Diameter (LVESD), after a single administration (1th group), two administrations (2nd group), or three administrations (3rd group). Results were expressed as mean ± S.E.M. from 4 mice/group. Data were analyzed by Student’s t-test. * p < 0.05, and ** p < 0.005 vs. control; and # p < 0.05 DZX+DOXO vs. DOXO.
| 24 h | Control | DOXO | DZX | DZX+DOXO | |
| LVEDD | 3.97 ± 0.11 | 4.09 ± 0.1 | 3.8 ± 0.010 | 3.725 ± 0.145 | |
| LVESD | 2.62 ± 0.17 | 3.00 ± 0.06 * | 2.8 ± 0.40 | 2.67 ± 0.146 | |
| %EF | 62.17 ± 4.1 | 52.7 ± 1.38 ** | 53.0 ± 5.0 | 54.25 ± 1.8 # | |
| %FS | 30.41 ± 0.72 | 26.6 ± 0.92 * | 27.0 ± 3.000 | 27.5 ± 0.936 # | |
| 3 days | Control | DOXO | DZX | DZX+DOXO | |
| LVEDD | 3.940 ± 0.050 | 3.96 ± 0.06 | 3.895 ± 0.005 | 3.792 ± 0.086 | |
| LVESD | 2.780 ± 0.054 | 2.90 ± 0.056 * | 2.70 ± 0.400 | 2.823 ± 0.107 | |
| %EF | 57.20 ± 1.25 | 53.73 ± 1.61 * | 70.0 ± 1.000 | 50.500 ± 2.217 | |
| %FS | 30.410 ± 0.850 | 27.43 ± 1.02 * | 39.5 ± 0.500 | 25.000 ± 0.354 # | |
| 7 days | Control | DOXO | DZX | DZX+DOXO | |
| LVEDD | 3.860 ± 0.040 | 3.96 ± 0.055 * | 3.515 ± 0.055 | 3.710 ± 0.079 | |
| LVESD | 2.730 ± 0.150 | 2.9 ± 0.14 | 2.350 ± 0.350 | 2.553 ± 0.135 | |
| %EF | 59.000 ± 4.170 | 50.49 ± 4.79 ** | 63.0 ± 2.000 | 57.00 ± 2.606 # | |
| %FS | 31.760 ± 1.680 | 25.39 ± 3.02 * | 32.00 ± 2.000 | 29.000 ± 1.517 # |